Funding breakthrough therapies: A systematic review and recommendation

In the 21st century, scientific advances have led to a better understanding of numerous diseases and a fast pace of innovation [1]; innovative breakthrough therapies have emerged to treat conditions and diseases that were previously considered incurable. Among innovative therapies, there is a class of biopharmaceuticals, called Advanced Therapy Medicinal Products (ATMPs) in Europe, that include somatic cell therapies, gene therapies and tissue-engineered products [2]. This class encompasses very promising therapies in development or already approved for the treatment of conditions in a variety of therapeutic areas, including oncology, cardiology, neurology and others [3,4].

Source: Health Policy - November 30, 2017 Category: Health Management Authors: E. Hanna, M. Toumi, C. Dussart, B. Borissov, O. Dabbous, K. Badora, P. Auquier Source Type: research